BOPA 2023 | How has COVID-19 changed the treatment landscape of prostate cancer?

Diana Matthews, Velindre Cancer Centre, Cardiff, UK, discusses changes in treating metastatic hormone-sensitive prostate cancer (mHSPC) brought about by the COVID-19 pandemic. Whilst docetaxel has been normally the standard of care, the pandemic made this unfeasible due to lockdowns. Novel hormone therapies such as enzalutamide, abiraterone and apalutamide are alternatives that have surpassed chemotherapy as a treatment strategy in terms of convenience and overall survival outcomes. This interview took place at the 26th Annual British Oncology Pharmacy Association (BOPA) Symposium in Newport, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.